Tissue-specific immune responses to vaccines refer to how the immune system’s reaction to a vaccine can vary depending on the tissue or organ targeted. Different tissues, such as the skin, lungs, or mucosal surfaces, may require distinct immune responses to ensure effective protection. For example, a vaccine targeting the respiratory system may generate a localized immune response in the lungs, while a vaccine administered intramuscularly might induce a broader systemic immune response. Understanding these tissue-specific responses is critical for designing vaccines that are optimized for specific pathogens or disease sites. Research into tissue-specific immunity helps create vaccines with enhanced efficacy, as they can be tailored to activate the appropriate immune cells and responses where they are needed most. This approach has significant implications for diseases that involve specific tissues, such as respiratory infections or gastrointestinal diseases, improving the precision and effectiveness of vaccines.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States